|
Editorial: IJPC-What it is!
Periodically, it is good to sit back and look at who we are and to clarify to those interested in compounding pharmacy what the International Journal of Pharmaceutical Compounding, Inc. (IJPC) involves. IJPC is an independent, private corporation (incorporated in the State of Oklahoma) and is not associated with any organization or company. It is owned primarily by independent pharmacists who were aware of a need over 10 years ago for a quality journal to represent pharmacy compounding. Today, IJPC provides the following products and services.
International Journal of Pharmaceutical Compounding (IJPC) Print and Electronic
Publication of the journal (IJPC) on a bimonthly schedule has been continuous since January 1997. IJPC is both a referenced and a reference journal. It has worldwide distribution and covers any topic related to compounding that might affect the practice of pharmaceutical compounding. It covers scientific, technical, marketing, social, political, and other aspects of compounding. A subscription includes BOTH the print and electronic versions. Accompanying the publication of IJPC is the free website, www.ijpc.com, where individuals can search for articles and other valuable information.
CompoundingToday.Com
CompoundingToday.com is another of IJPC's websites, which contains free information as well as modules available on a subscription basis. It is becoming the world's largest electronic resource for compounding information and is available 24/7.
Free information includes (1) current issue of the weekly e-Newsletter, (2) Trial subscription form, (3) Compounders' Network List (CNL) registration access, and (4) an educational courses listing for sterile and nonsterile compounding information.
There are 3 modules of subscription-based information, as follows:
Basic Module includes (1) bacterial endotoxin level data and calculation form, (2) base-salt-ester weight conversions, (3) chemotherapy vial reconstitution and stability, (4) disinfectants, (5) chemical filter membrane compatibility, (6) flavoring guides, (7) sodium chloride equivalent values and tonicity adjustment (8) oleaginous vehicles, (9) oral vehicles, (10) pH adjustment, (11) preservatives and antioxidants, (12) veterinary transdermals, (13) physicochemical properties of active drugs and excipients, (14) GAP analysis for USP <797> and <795>, (15) drug information compounding article literature search, (16) discontinued medications database, (17) compliance section links to information from NIOSH, FDA, USP, PCAB, and DEA, (18) interactive claim form, (19) newsletter archives, and (20) White Papers.
Module 2 includes standard operating procedures in Word format and compounding formulations.
Module 3 includes Trissel's 2 Clinical Pharmaceutics Database, the largest database of stability and compatibility information ever assembled. It contains five times the amount of information generally found in published reference works.
Compounders' Network List
This is a free service allowing compounding pharmacists worldwide to ask and answer questions regarding compounding. It is moderated and is operational seven days a week. One can join by going to the IJPC.com or CompoundingToday.com web sites.
CompoundingToday.com Weekly Newsletter
This is a free service providing news, editorials, tips, and other compounding information that is electronically distributed every Friday.
Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
|
|
Note from the FDLI SmartBrief, Food and Drug Law Institute September 27, 2007
Millions of unapproved prescription drugs are given to patients every year by doctors and pharmacists, most of whom are unaware that the FDA has not yet allowed such drugs into the U.S. market, CNN reports. The FDA has recently started investigating this practice and says it has been issuing more warnings and has pulled some medicines from the market. "Some of these products -- not the majority -- but some of these products are medically necessary," FDA compliance chief Deborah Autor said.
Note from Journal Watch, September 15, 2007
Direct to consumer (DTC) advertising of prescription drugs increased from about $1 billion in 1996 to $4 billion in 2005.
From 2002 to 2006, DTC advertising was the target of one third to one half of letters sent by the FDA to drug companies regarding violations in regulations on drug promotion. Most citations were for DTC advertising that minimized risks or exaggerated effectiveness.
|
